JCGA: the Japanese version of the Cancer Genome Atlas and its contribution to the interpretation of gene alterations detected in clinical cancer genome sequencing.


Journal

Human genome variation
ISSN: 2054-345X
Titre abrégé: Hum Genome Var
Pays: England
ID NLM: 101652445

Informations de publication

Date de publication:
30 Sep 2021
Historique:
received: 07 05 2021
accepted: 03 09 2021
revised: 31 08 2021
entrez: 30 9 2021
pubmed: 1 10 2021
medline: 1 10 2021
Statut: epublish

Résumé

With the emergence of next-generation sequencing (NGS)-based cancer gene panel tests in routine oncological practice in Japan, an easily interpretable cancer genome database of Japanese patients in which mutational profiles are unaffected by racial differences is needed to improve the interpretation of the detected gene alterations. Considering this, we constructed the first Japanese cancer genome database, called the Japanese version of the Cancer Genome Atlas (JCGA), which includes multiple tumor types. The database includes whole-exome sequencing data from 4907 surgically resected primary tumor samples obtained from 4753 Japanese patients with cancer and graphically provides genome information on 460 cancer-associated genes, including the 336 genes that are included in two NGS-based cancer gene panel tests approved by the Pharmaceuticals and Medical Devices Agency. Moreover, most of the contents of this database are written in Japanese; this not only helps physicians explain the results of NGS-based cancer gene panel tests but also enables patients and their families to obtain further information regarding the detected gene alterations.

Identifiants

pubmed: 34588443
doi: 10.1038/s41439-021-00170-w
pii: 10.1038/s41439-021-00170-w
pmc: PMC8481308
doi:

Types de publication

Journal Article

Langues

eng

Pagination

38

Subventions

Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 19K07792

Informations de copyright

© 2021. The Author(s).

Références

JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Trends Cancer. 2017 Mar;3(3):181-197
pubmed: 28718431
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Hum Genomics. 2016 Jan 16;10:4
pubmed: 26772741
Cancer Sci. 2021 Mar;112(3):970-977
pubmed: 33289217
Genomics. 2019 Dec;111(6):1529-1542
pubmed: 30366040
Cancer Sci. 2018 Mar;109(3):507-512
pubmed: 29285848
Nat Genet. 2017 Jan 31;49(2):170-174
pubmed: 28138153
Biomed Res. 2014;35(6):407-12
pubmed: 25743347
Sci Rep. 2017 Oct 20;7(1):13639
pubmed: 29057889
Nat Methods. 2016 Sep 29;13(10):806-7
pubmed: 27684579
Cancer Sci. 2020 Feb;111(2):687-699
pubmed: 31863614
Sci Rep. 2019 Aug 5;9(1):11340
pubmed: 31383922
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Melanoma Res. 2008 Feb;18(1):29-35
pubmed: 18227705

Auteurs

Masakuni Serizawa (M)

Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan. m.serizawa@scchr.jp.
Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan. m.serizawa@scchr.jp.

Maki Mizuguchi (M)

Shizuoka Cancer Center, Shizuoka, Japan.

Kenichi Urakami (K)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Takeshi Nagashima (T)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
SRL, Tokyo, Japan.

Keiichi Ohshima (K)

Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Keiichi Hatakeyama (K)

Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Sumiko Ohnami (S)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Shumpei Ohnami (S)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Koji Maruyama (K)

Experimental Animal Facility, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Tadashi Ashizawa (T)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Akira Iizuka (A)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Yasue Horiuchi (Y)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Akane Naruoka (A)

Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Hirotsugu Kenmotsu (H)

Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Division of Genetic Medicine Promotion, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

Yasuto Akiyama (Y)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Ken Yamaguchi (K)

Shizuoka Cancer Center, Shizuoka, Japan.

Classifications MeSH